Platinum-resistant ovarian cancer remains a significant and complex clinical challenge. In this episode of Precision in Practice, a physician-led Saudi expert panel discusses the unmet need in platinum-resistant ovarian cancer, the importance of early FRα biomarker testing, the evolving role of antibody-drug conjugates, and practical treatment-management considerations.

Topics discussed include:

• The clinical burden of platinum-resistant ovarian cancer
• FRα testing and biomarker-driven treatment selection
• The role of antibody-drug conjugates
• Key findings from the MIRASOL trial
• Patient preparation and multidisciplinary coordination
• Ocular toxicity prevention, monitoring, and management
• Additional safety and practical treatment considerations

PANEL

Host: Dr. Mohamed Aseafan
Consultant Medical Oncologist
Security Forces Hospital, Riyadh

Panelists:

Dr. Hashim Alhashim
Consultant Medical Oncologist
King Khalid University Hospital, Riyadh

Dr. Nashmia Almutairi
Consultant Gynecological Oncologist
National Guard Hospital, Riyadh

Dr. Faisal Azam
Consultant Medical Oncologist
King Fahad Specialized Hospital, Dammam

Dr. Wala Mehros
Consultant Gynecological Oncologist
National Guard Hospital, Jeddah

IMPORTANT INFORMATION

This program is intended primarily for healthcare professionals and is provided for scientific and educational purposes only.

It does not constitute personal medical advice or replace independent clinical judgment. Treatment decisions should be based on the applicable approved prescribing information, local regulatory approval, current clinical guidance, institutional protocols, and the individual needs of each patient.

The views expressed by the participating physicians are their own and do not necessarily represent the views or policies of their respective institutions, Aspire Impact Solutions, or any supporting organization.

SPONSORSHIP DISCLOSURE

This episode is sponsored by AbbVie Biopharmaceuticals GmbH-Saudi Arabia. The views expressed are those of the participating healthcare professionals and do not necessarily reflect the views of AbbVie Biopharmaceuticals GmbH, their respective institutions, or Aspire Impact Solutions.

Produced by Aspire Impact Solutions (AIS)
Website: https://www.aspire-impact.com/
Privacy Policy: https://www.aspire-impact.com/privacy-policy
Contact: admin@aspire-impact.com